Physiology Research Center, Kerman University of Medical Sciences, Kerman, 7616914115, Iran.
Endocrinology, and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, 7616914115, Iran.
Chin J Integr Med. 2022 Jun;28(6):531-537. doi: 10.1007/s11655-022-3307-3. Epub 2022 Mar 8.
To evaluate the effect of Shilajit, a medicine of Ayurveda, on the serum changes in cytokines and adipokines caused by non-alcoholic fatty liver disease (NAFLD).
After establishing fatty liver models by feeding a high-fat diet (HFD) for 12 weeks, 35 Wistar male rats were randomly divided into 5 groups, including control (standard diet), Veh (HFD + vehicle), high-dose Shilajit [H-Sh, HFD + 250 mg/(kg·d) Shilajit], low-dose Shilajit [L-Sh, HFD + 150 mg/(kg·d) Shilajit], and pioglitazone [HFD + 10 mg/(kg·d) pioglitazone] groups, 7 rats in each group. After 2-week of gavage administration, serum levels of glucose, insulin, interleukin 1beta (IL-1β), IL-6, IL-10, tumor necrosis factor-alpha (TNF-α), adiponectin, and resistin were measured, and insulin resistance index (HOMA-IR) was calculated.
After NAFLD induction, the serum level of IL-10 significantly increased and serum IL-1β, TNF-α levels significantly decreased by injection of both doses of Shilajit and pioglitazone (P<0.05). Increases in serum glucose level and homeostasis model of HOMA-IR were reduced by L-Sh and H-Sh treatment in NAFLD rats (P<0.05). Both doses of Shilajit increased adiponectin and decreased serum resistin levels (P<0.05).
The probable protective role of Shilajit in NAFLD model rats may be via modulating the serum levels of IL-1β, TNF-α, IL-10, adipokine and resistin, and reducing of HOMA-IR.
评估希拉杰特（一种阿育吠陀药物）对非酒精性脂肪肝（NAFLD）引起的细胞因子和脂肪因子血清变化的影响。
通过高脂饮食（HFD）喂养 12 周建立脂肪肝模型后，将 35 只雄性 Wistar 大鼠随机分为 5 组，包括对照组（标准饮食）、Veh 组（HFD+载体）、高剂量希拉杰特[H-Sh，HFD+250mg/（kg·d）希拉杰特]、低剂量希拉杰特[L-Sh，HFD+150mg/（kg·d）希拉杰特]和吡格列酮[HFD+10mg/（kg·d）吡格列酮]组，每组 7 只。灌胃 2 周后，测定血清葡萄糖、胰岛素、白细胞介素 1β（IL-1β）、IL-6、IL-10、肿瘤坏死因子-α（TNF-α）、脂联素和抵抗素水平，并计算胰岛素抵抗指数（HOMA-IR）。
NAFLD 诱导后，两剂量希拉杰特和吡格列酮注射均可使血清 IL-10 水平显著升高，血清 IL-1β和 TNF-α水平显著降低（P<0.05）。L-Sh 和 H-Sh 治疗可降低 NAFLD 大鼠血清葡萄糖水平和 HOMA-IR 升高（P<0.05）。两剂量希拉杰特均可增加脂联素，降低血清抵抗素水平（P<0.05）。
希拉杰特可能通过调节血清中 IL-1β、TNF-α、IL-10、脂联素和抵抗素水平，降低 HOMA-IR，在 NAFLD 模型大鼠中发挥保护作用。
